Home › SEC Filings › Current Report (8-K)
Current Report (8-K)
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| SXTP | 8-K | neutral | 5/10 | 🔒60 Degrees Pharmaceuticals announced positive results from its expanded access study of tafenoquine combination regimens | Oct 27, 2026 |
| ENTX | 8-K | neutral | 3/10 | 🔒Entera Bio appointed Dr. Juan Camilo Arjona Ferreira, Head of R&D and CMO at Organon, to its Board of Directors effectiv | Oct 27, 2026 |
| ZURA | 8-K | neutral | 5/10 | 🔒Zura Bio reported a net loss of $25.8 million ($0.20 per share) for Q3 2026, compared to a net loss of $18.0 million ($0 | Oct 27, 2026 |
| WVE | 8-K | bullish | 6/10 | 🔒Wave Life Sciences reported Q3 2026 revenue of $13.2M (up 73% YoY from $7.6M) and a GAAP net loss of $61.9M ($-0.30 per | Oct 27, 2026 |
| FTH | 8-K | neutral | 2/10 | 🔒Faeth Therapeutics appointed Adam Schayowitz, Ph.D., as a Class III director, expanding the board from six to seven memb | Oct 27, 2026 |
| KNSA | 8-K | bullish | 6/10 | 🔒Kiniksa reported Q3 2026 ARCALYST net product revenue of $286.0M, up ~58% YoY, and raised full-year 2026 ARCALYST guidan | Oct 27, 2026 |
| IQV | 8-K | bullish | 6/10 | 🔒IQVIA reported Q3 2026 revenue of $4,428M (up 8.0% YoY) and adjusted diluted EPS of $3.34 (up 11.3% YoY), exceeding cons | Oct 27, 2026 |
| RGEN | 8-K | bullish | 6/10 | 🔒Repligen reported Q3 2026 revenue of $209.3M, up 11% YoY as reported and 12.5% organic, beating the $206.7M consensus. A | Oct 27, 2026 |
| ACRS | 8-K | bullish | 6/10 | 🔒Aclaris Therapeutics reported positive Phase 1b proof-of-concept primary analysis results for its anti-TSLP/IL-4R bispec | Oct 27, 2026 |
| IMNN | 8-K | neutral | 2/10 | 🔒Imunon filed an 8-K to announce that it made an investor presentation available for use in investor calls and conference | Oct 27, 2026 |
| WST | 8-K | neutral | 4/10 | 🔒West Pharmaceutical Services entered into a new $950 million unsecured credit agreement on October 26, 2026, consisting | Oct 26, 2026 |
| EQ | 8-K | bearish | 6/10 | 🔒Equillium dosed the first subject in a Phase 1 trial of EQ504, triggering a $20 million milestone closing under its Augu | Oct 26, 2026 |
| ONCO | 8-K | neutral | 3/10 | 🔒Onconetix announced a second 1-for-10 reverse stock split, effective November 6, 2026, reducing outstanding shares from | Oct 26, 2026 |
| RLYB | 8-K | neutral | 5/10 | 🔒Rallybio Corp's board declared a special cash distribution of approximately $82.7 million ($13.56 per share) to stockhol | Oct 26, 2026 |
| MIRM | 8-K | bullish | 6/10 | 🔒Mirum Pharmaceuticals announced positive Phase 3 PROGRESS Cohort 2 results for ATEBRIOZ (zilurgisertib) in pediatric FOP | Oct 26, 2026 |
| LGVN | 8-K | neutral | 5/10 | 🔒Longeveron announced updated results from its ELPIS II Phase 2b trial of laromestrocel in HLHS. The trial missed the pri | Oct 26, 2026 |
| SUPN | 8-K | neutral | 2/10 | 🔒Supernus Pharmaceuticals terminated its uncommitted demand revolving UBS Credit Line on October 20, 2026, in anticipatio | Oct 26, 2026 |
| CVSI | 8-K | neutral | 2/10 | 🔒CV Sciences settled its JAMS arbitration against former legal counsel, receiving $500,000 and mutually releasing all cla | Oct 26, 2026 |
| CPIX | 8-K | neutral | 5/10 | 🔒Cumberland Pharmaceuticals announced plans to submit a New Drug Application (NDA) to the FDA for ifetroban as a treatmen | Oct 26, 2026 |
| MCRB | 8-K | bearish | 5/10 | 🔒Seres Therapeutics CFO Marella Thorell resigned effective November 15, 2026, and will provide advisory services for an o | Oct 26, 2026 |
| SNTI | 8-K | bearish | 7/10 | 🔒Senti Biosciences completed its merger with a Celadon Partners affiliate, divesting its operating subsidiary (Midco/Opco | Oct 26, 2026 |
| ETST | 8-K | neutral | 3/10 | 🔒Earth Science Tech, Inc. announced the resignation of CFO and board member Ernesto L. Flores, effective October 25, 2026 | Oct 26, 2026 |
| CTXR | 8-K | neutral | 4/10 | 🔒Citius Oncology reported preliminary Q4 FY2026 LYMPHIR unit sales of 792 units to U.S. wholesalers, up 120% from 360 uni | Oct 26, 2026 |
| CTOR | 8-K | neutral | 5/10 | 🔒Citius Oncology reported preliminary fiscal Q4 2026 LYMPHIR unit sales of 792 units to U.S. wholesalers, up 120% from 36 | Oct 26, 2026 |
| JAZZ | 8-K | bearish | 6/10 | 🔒Jazz Pharmaceuticals filed an 8-K estimating a pre-tax charge of approximately $755 million for acquired IPR&D expense r | Oct 26, 2026 |
| XBIT | 8-K | neutral | 3/10 | 🔒XBiotech Inc. filed an 8-K announcing the appointment of Dr. Sushma Shivaswamy and Jan-Paul Simard as Co-Chief Executive | Oct 26, 2026 |
| NEOG | 8-K/A | neutral | 2/10 | 🔒This 8-K/A amends the original 8-K filed on October 7, 2026, to add Item 5.02 disclosure regarding shareholder approval | Oct 26, 2026 |
| OTLC | 8-K | neutral | 2/10 | 🔒Oncotelic Therapeutics filed an 8-K to report that its Chief Business Officer presented a research framework (Partitione | Oct 26, 2026 |
| AZTR | 8-K | neutral | 4/10 | 🔒Azitra announced positive ex vivo data for its ATR-COSF cosmetic product candidate, showing up to ~50% reduction in fine | Oct 26, 2026 |
| APVO | 8-K | neutral | 4/10 | Aptevo Therapeutics announced that 10 of 47 (21%) evaluable frontline AML patients treated with mipletamig in combinatio | Oct 26, 2026 |
Page 1 of 106 Next »